PD-1/PD-L1-IN-10

• UNSPSC Description:

  PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy[1].

• Target Antigen:

  Apoptosis; PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Immunology/Inflammation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pd-1-pd-l1-in-10.html

• Purity:

  99.61

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC1=C(C=CC=C1C2=CC=CC=C2)COC3=C(C=C(C(OCC4=CC(C#N)=CC=C4)=C3)CN[C@H](C(O)=O)C(O)C)[N+]([O-])=O

• Molecular Weight:

  581.62

• References & Citations:

  [1]Yiqiang OuYang, et al. Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo. J Med Chem. 2021 May 26.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2487550-41-2